Provided by Tiger Fintech (Singapore) Pte. Ltd.

Crinetics Pharmaceuticals Inc.

31.20
-0.5700-1.79%
Post-market: 31.200.00000.00%17:24 EDT
Volume:533.61K
Turnover:16.64M
Market Cap:2.92B
PE:-8.17
High:32.00
Open:32.00
Low:30.94
Close:31.77
Loading ...

What Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)?

Insider Monkey
·
30 Jan

Jefferies Upgrades Crinetics Pharmaceuticals to Buy From Hold, $55 Price Target

MT Newswires Live
·
22 Jan

Crinetics Pharmaceuticals Raised to Buy From Hold by Jefferies

Dow Jones
·
22 Jan

Crinetics upgraded to Buy from Hold at Jefferies

TIPRANKS
·
22 Jan

Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Insider Monkey
·
22 Jan

Oppenheimer Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

TIPRANKS
·
13 Jan

Crinetics Pharmaceuticals Price Target Maintained With a $81.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Jan

BRIEF-Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
11 Jan

Crinetics data ‘compelling’ despite safety concerns, says Leerink

TIPRANKS
·
11 Jan

Crinetics CAH data ‘okay,’ but expectations were high, says Jefferies

TIPRANKS
·
11 Jan

Crinetics Shares Fall After Reporting 'Positive' Phase 2 Results for Congenital Adrenal Hyperplasia Treatment

MT Newswires Live
·
11 Jan

Crinetics Pharmaceuticals Down Nearly 9%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk

Dow Jones
·
11 Jan

Crinetics announces results from Phase 2 trial of atumelnant

TIPRANKS
·
10 Jan

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (Cah)

THOMSON REUTERS
·
10 Jan

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

GlobeNewswire
·
10 Jan